×
About 1,343,933 results

Commentary: HER2+-targeted therapy, ovarian suppression, and adjuvant therapy in breast cancer, February 2023
https://www.mdedge.com/hematology-oncology/article/260902/breast-cancer/commentary-her2-targeted-therapy-ovarian
Erin Roesch, MD

Jan 27th, 2023 - Erin Roesch, MD Standard first-line therapy for human epidermal growth factor receptor 2 positive (HER2+, ERBB2+) metastatic breast cancer (MBC) includes dual-HER2 blockade (trastuzumab + pertuzumab) in combination with a taxane. 1,2 Differences according to hormone receptor status within HER2+ MBC have been demonstrated in clinicopathologic features, survival, and treatment response.

Commentary: A New Drug, and Pediatric Concerns, February 2023
https://www.mdedge.com/dermatology/article/260900/atopic-dermatitis/commentary-new-drug-and-pediatric-concerns-february
Steven R. Feldman, MD, PhD

Jan 27th, 2023 - Steven R. Feldman, MD, PhD I suspect lebrikizumab is going to be another excellent atopic dermatitis (AD) treatment option.

Fluorescence-optical imaging may detect preclinical PsA
https://www.mdedge.com/rheumatology/article/260899/psoriatic-arthritis/fluorescence-optical-imaging-may-detect-preclinical
Heidi Splete

Jan 27th, 2023 - Fluorescence-optical imaging (FOI) identified early signs of psoriatic arthritis, based on data from 2 years of follow-up of a cohort of 389 adults at 14 rheumatology centers. Approximately 25% of individuals with psoriasis go on to develop psoriatic arthritis (PsA), but there are no validated biomarkers to identify patients at risk for progression to PsA, Michaela Koehm, MD, of Goethe Universi.

Infant with red eyelid lesion
https://www.mdedge.com/familymedicine/article/260897/pediatrics/infant-red-eyelid-lesion
MDedge Family Medicine; Jimena G. Cervantes, MD, Richard P. Usatine, MD

Jan 27th, 2023 - A 4-MONTH-OLD HISPANIC INFANT was brought to her pediatrician by her parents for evaluation of a dark red lesion over her right eyelid. The mother said that the lesion appeared when the child was 4 weeks old and started as a small red dot.

Metabolic syndromes worsen outcomes in BC patients treated with neoadjuvant chemotherapy
https://www.mdedge.com/breast-cancer-icymi/article/260893/breast-cancer/metabolic-syndromes-worsen-outcomes-bc-patients

Jan 27th, 2023 - Key clinical point: The presence of metabolic syndromes (MetS) worsened survival outcomes and increased disease recurrence risk in patients with breast cancer (BC) who received neoadjuvant chemotherapy (NAC). Major finding: The MetS group had a significantly lower likelihood of achieving pathological complete response than the non-MetS group (odds ratio [ OR] 0.

Metastatic BC: Not worth changing the 4-weekly schedule of pegylated liposomal doxorubicin
https://www.mdedge.com/breast-cancer-icymi/article/260892/breast-cancer/metastatic-bc-not-worth-changing-4-weekly-schedule

Jan 27th, 2023 - Key clinical point: Recent phase 2 trials have recommended a 2-weekly schedule of pegylated liposomal doxorubicin (PLD) in patients with heavily treated metastatic breast cancer (BC); however, it failed to demonstrate any advantage in terms of efficacy or safety over the registered 4-weekly regimen of PLD. Major finding: The median progression-free survival was 3.

Early autologous fat grafting associated with increased BC recurrence risk
https://www.mdedge.com/breast-cancer-icymi/article/260891/breast-cancer/early-autologous-fat-grafting-associated-increased

Jan 27th, 2023 - Key clinical point: Autologous fat grafting (AFG) in the second stage of a 2-stage prosthetic breast reconstruction was linked to a higher risk for breast cancer (BC) recurrence when performed within a year after mastectomy. Major finding: Patients who did vs did not undergo AFG within 1 year after the primary operation had a significantly increased risk for disease recurrence (hazard ratio 5.

Meta-analysis compares adjuvant chemotherapy regimens for resected early-stage TNBC
https://www.mdedge.com/breast-cancer-icymi/article/260890/breast-cancer/meta-analysis-compares-adjuvant-chemotherapy

Jan 27th, 2023 - Key clinical point: In patients with early-stage triple-negative breast cancer (TNBC), adding capecitabine to classic anthracycline/taxane-based adjuvant chemotherapy improved overall survival (OS) and carboplatin/paclitaxel was the most effective regimen for improving disease-free survival (DFS). Major finding: Adjuvant chemotherapy with anthracyclines/taxanes plus capecitabine vs anthracyclin.

Overall survival improved with chemotherapy in ER-negative/HER2-negative, T1abN0 BC
https://www.mdedge.com/breast-cancer-icymi/article/260889/breast-cancer/overall-survival-improved-chemotherapy-er-negative

Jan 27th, 2023 - Key clinical point: Treatment with adjuvant chemotherapy significantly improved overall survival (OS) outcomes in patients with estrogen receptor-negative (ER−)/human epidermal growth factor receptor 2-negative (HER2−), T1abN0 breast cancer (BC). Major finding: After a median follow-up of 7.

ERBB2 mRNA expression predicts prognosis in trastuzumab emtansine-treated advanced HER2+ BC patients
https://www.mdedge.com/breast-cancer-icymi/article/260888/breast-cancer/erbb2-mrna-expression-predicts-prognosis

Jan 27th, 2023 - Key clinical point: In patients with advanced human epidermal growth factor receptor 2-positive ( HER2+ or ERBB2+) breast cancer (BC) treated with trastuzumab emtansine, the pre-established levels of ERBB2 mRNA expression according to the HER2DX standardized assay served as an important prognostic biomarker in predicting survival outcomes. Major finding: High, medium, and low levels of ERBB2 mR.

Addition of atezolizumab to carboplatin+paclitaxel improves pCR in stage II-III TNBC
https://www.mdedge.com/breast-cancer-icymi/article/260887/breast-cancer/addition-atezolizumab-carboplatinpaclitaxel

Jan 27th, 2023 - Key clinical point: Addition of atezolizumab to carboplatin+paclitaxel in the neoadjuvant setting improved the pathological complete response (pCR) rate in patients with stage II-III triple-negative breast cancer (TNBC). Major finding: After a median follow-up of 6.

Gut enzymes fingered in some 5-ASA treatment failures
https://www.mdedge.com/internalmedicine/article/260886/gastroenterology/gut-enzymes-fingered-some-5-asa-treatment-failures
Neil Osterweil

Jan 27th, 2023 - AURORA, COLO. – The therapeutic action of 5-aminosalicylic acid (5-ASA), one of the most frequently prescribed drugs for inflammatory bowel disease (IBD), can be defeated by enzymes that reside in the very gut that the drug is designed to treat.

ER/PgR+ BC: Adjuvant exemestane+ovarian suppression reduces recurrence risk
https://www.mdedge.com/breast-cancer-icymi/article/260885/breast-cancer/er/pgr-bc-adjuvant-exemestaneovarian-suppression

Jan 27th, 2023 - Key clinical point: Exemestane plus ovarian function suppression (OFS) led to a greater reduction in recurrence risk than tamoxifen+OFS in premenopausal women with estrogen or progesterone receptor-positive (ER/PgR+) early breast cancer (BC). Major finding: There was a significant improvement in 12-year disease-free survival (hazard ratio [ HR] 0.

Adding SBRT to sorafenib boosts survival in liver cancer
https://www.mdedge.com/hematology-oncology/article/260884/gastrointestinal-cancer/adding-sbrt-sorafenib-boosts-survival
Roxanne Nelson, RN, BSN

Jan 27th, 2023 - SAN FRANCISCO – Adding stereotactic body radiation therapy (SBRT) to sorafenib produced better outcomes among patients with hepatocellular carcinoma (HCC) than sorafenib alone, according to new findings. The use of SBRT in this setting improved both overall survival and progression-free survival (PFS).

Reported Human Infections with Avian Influenza A Viruses
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/639466

Human infections with avian influenza A viruses are uncommon but have occurred sporadically in many countries.

Tips and tools to help you manage ADHD in children, adolescents
https://www.mdedge.com/familymedicine/article/260883/pediatrics/tips-and-tools-help-you-manage-adhd-children-adolescents
MDedge Family Medicine; Sundania Wonnum, PhD, LCSW, Jamie Krassow, MD

Jan 27th, 2023 - THE CASE James B* is a 7-year-old Black child who presented to his primary care physician (PCP) for a well-child visit. During preventive health screening, James’ mother expressed concerns about his behavior, characterizing him as immature, aggressive, destructive, and occasionally self-loathing.

Does physical exercise reduce dementia-associated agitation?
https://www.mdedge.com/familymedicine/article/260882/neurology/does-physical-exercise-reduce-dementia-associated-agitation
MDedge Family Medicine; Katarzyna Jabbour, PharmD, BCPS, Lynn M. Wilson, DO, FACOFP, FAAFP et. al.

Jan 27th, 2023 - Evidence summary Mixed results on exercise’s effect on neuropsychiatric symptoms A 2020 systematic review and meta-analysis of 18 RCTs investigated the effect of home-based physical activity on several markers of behavioral and psychological symptoms of dementia (BPSD). These symptoms were measured using the caregiver-completed neuropsychiatric inventory (NPI), which includes agitation.

Adding veliparib to cisplatin improves PFS in BRCA-like metastatic TNBC
https://www.mdedge.com/breast-cancer-icymi/article/260881/breast-cancer/adding-veliparib-cisplatin-improves-pfs-brca

Jan 27th, 2023 - Key clinical point: In patients with germline BRCA1/2-wildtype metastatic triple-negative breast cancer (TNBC) with a BRCA-like phenotype, cisplatin plus veliparib significantly improved progression-free survival (PFS) without causing any unprecedented adverse events. Major finding: PFS was significantly improved with cisplatin+veliparib vs cisplatin+placebo (hazard ratio 0.

For Public Health Veterinarians and Animal Health Officials
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/730319

Mpox - Guide for Public Health Veterinarians and Animal Health Officials

COVID Risk Up to 50% Higher for Nursing Home Residents Behind on Vaccination
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/102865

Jan 27th, 2023 - Nursing home residents who were not up to date with their COVID-19 vaccines had a 30% to 50% higher risk of getting infected compared with those who were up to date, CDC researchers said. From Oct. 10, 2022 to Jan. 8, 2023, weekly COVID incidence rates ranged from 7.2 to 15.6 per 1,000 nursing home residents among those who were up to date with vaccinations compared with rates of 9.5 to 18.8 pe...